

# Impaired Glutamatergic and GABAergic function at Early Age in APP<sup>swE</sup>-PS1<sup>dE9</sup> Mice: Implications for Preclinical Diagnosis of Alzheimer's Disease


Vivek Tiwari<sup>1</sup>, and Anant Bahadur Patel<sup>1</sup>

<sup>1</sup>NMR Microimaging and Spectroscopy, Centre for Cellular and Molecular Biology, Hyderabad, Andhra Pradesh, India

**INTRODUCTION:** Alzheimer's disease (AD) is one of the very common neurodegenerative disorders, characterized by neuritic plaques and neurofibrillary tangles marked with loss of cognitive functions and memory impairment<sup>1</sup>. As there is no effective treatment available for AD, a paradigm shift in AD research is towards the early diagnosis and interventions for delay of the disease. APP-PS1 mice exhibit increase in amyloid plaques with age and more closely match the neurochemical profile and pathology of human AD<sup>2</sup>. Moreover, these mice show occasional deposits of amyloid plaques at the age of 5-6 months without significant memory impairment and neuronal loss- characteristics typical of AD pathology at an early stage of the disease<sup>3</sup>. The objective of the present study is to investigate neuronal metabolism in APP-PS1 mice at 6 month to find out biomarker for the early diagnosis of AD.

**MATERIALS AND METHODS:** All animal experiments were performed under approved protocols by the Institute Animal Ethics Committee. Overnight fasted APP-PS1 (6 month, n=6) and age matched wild-type (n=6) mice were anesthetized with urethane (1 g/kg, ip). [1,6-<sup>13</sup>C<sub>2</sub>]Glucose was infused for 10 min through tail vein using bolus variable infusion rate<sup>4</sup>. In addition, mice were also infused with [1,6-<sup>13</sup>C<sub>2</sub>]glucose for 90 min to evaluate labeling at steady state. Blood was collected and head was frozen *in situ* into liquid nitrogen at the end of infusion. Metabolites were extracted from frozen brain tissue<sup>5</sup>. Concentration and percentage <sup>13</sup>C enrichment of cerebral amino acids were measured in <sup>1</sup>H-[<sup>13</sup>C]-NMR spectra of tissue extracts acquired at 600 MHz spectrometer<sup>6</sup>.

**RESULTS AND DISCUSSIONS:** Neurometabolites level was not significantly different in APP-PS1 and wild-type mice. <sup>13</sup>C Labeling of cortical amino acids, Glu<sub>C4</sub>, GABA<sub>C2</sub>, Gln<sub>C4</sub>, Glu<sub>C3</sub> and Asp<sub>C3</sub> from [1,6-<sup>13</sup>C<sub>2</sub>]glucose was significantly (F[1,4]=52.54, p<0.01) lower in APP-PS1 mice than age matched wild-type (Fig. 1A). This together with no significant differences in the steady state labeling of amino acids suggest that glutamatergic TCA cycling is reduced in APP-PS1 mice. Nonlinear least-squares fitting to the time courses of Glu<sub>C4</sub> and GABA<sub>C2</sub> (Fig. 1B) to monoexponential function revealed that glucose oxidation associated with glutamatergic (Fig. 1C) and GABAergic neurons (Fig. 1D) is severely reduced in cerebral cortex of APP-PS1 at the early age of AD. Similar results were observed in the hippocampal and striatal regions of brain. These findings may have implications in the preclinical diagnosis of AD



**Fig.1** (A) Typical <sup>1</sup>H-[<sup>13</sup>C]-NMR spectra from cortical extract. (B) Turnover of Glu<sub>C4</sub> and GABA<sub>C2</sub> from [1,6-<sup>13</sup>C<sub>2</sub>]glucose in cerebral cortex. Rate of glucose oxidation by glutamatergic (C) GABAergic neurons in different regions of brain of APP-PS1 and Wild Type mice

**REFERENCES:** 1. Hardy *et al* (2002) *Science* **297**: 353; 2. Marjanska *et al* (2005) *Proc Natl Acad Sci* **102**:11906; 3. Vollianskis *et al* (2008) *Neurobiol Aging* **31**:1173 ; 4. Fitzpatrick *et al* (1990) *J Cereb Blood Flow Metab* **10**:170 ; 5. Patel *et al* (2001) *Brain Res* 919:207; 6. de Graaf *et al* (2003) *Magn Reson Med* **49**:37

**ACKNOWLEDGEMENTS:** This study was supported by funding from Department of Biotechnology, India.